Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis Merger Would Require Revasc Divestiture; Novartis Has First Rights

Executive Summary

Rhone-Poulenc Rorer would divest its direct thrombin inhibitor candidate Revasc (desirudin) in order to complete its merger with Hoechst Marion Roussel into Aventis, a Dec. 7 consent order provisionally accepted by the Federal Trade Commission states.

You may also be interested in...



Specialty Pharma Canyon Takes Leech-Inspired Anticoagulant Approved In 2003 To Market

Iprivask, "the first direct thrombin inhibitor approved in the U.S.," was found superior to both heparin and Lovenox but fell through the cracks during pharma M&A activity, Canyon exec says.

Aventis Retains Revasc; Refludan Divestment Ordered By FTC

Aventis' Refludan is available for licensing through the New York City investment banking company Ferghana Partners as a result of an Aug. 25 Federal Trade Commission order.

Aventis Retains Revasc; Refludan Divestment Ordered By FTC

Aventis' Refludan is available for licensing through the New York City investment banking company Ferghana Partners as a result of an Aug. 25 Federal Trade Commission order.

Related Content

UsernamePublicRestriction

Register

PS035288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel